August 20, 2025Open Access

m6A modification-mediated LINC01547 promotes pancreatic cancer growth and gemcitabine sensitivity through miR-34a-5p/MYH9 axis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis reveals LINC01547 promotes gemcitabine resistance in pancreatic cancer, indicating a potential therapeutic target.

Silencing LINC01547 significantly enhances gemcitabine sensitivity in pancreatic cancer cells, improving treatment outcomes.
LINC01547 expression was upregulated in pancreatic cancer tissues, correlating negatively with patient prognosis and survival.
Analysis involved RNA sequencing and luciferase reporter assays to confirm the role of miR-34a-5p targeting MYH9.
This research highlights the potential of targeting the LINC01547/miR-34a-5p/MYH9 axis to combat gemcitabine resistance in pancreatic cancer.

Lu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark